TY - JOUR
T1 - Chemotherapy of reticuloendotheliosis
T2 - Comparison of methotrexate plus prednisone vs. vincristine plus prednisone
AU - Jones, Barbara
AU - Kung, Faith
AU - Chevalier, Louise
AU - Forman, Edwin N.
AU - Rausen, Aaron
AU - Koch, Kjell
AU - Desposito, Franklin
AU - Maurer, Harold
AU - Jacquillat, Claude
AU - Degnan, Thomas J.
AU - Pluess, Hansjuerg
AU - Desforges, Jane
AU - Patterson, Richard B.
AU - Glidewell, Oliver
AU - Holland, James F.
PY - 1974/10
Y1 - 1974/10
N2 - Twenty‐eight children, ages 2 months to 13 years, with a diagnosis of reticuloendotheliosis were treated on a random basis with either vincristine (VCR) 2 mg/m2/week or methotrexate (MTX) 30 mg/m2 twice a week. Both groups received prednisone 40 mg/m2/day. The responders received randomly either MTX 30 mg/m2 twice weekly or no maintenance therapy. Of the 11 patients receiving VCR, 2 achieved complete and 5 partial remissions. Among 17 treated with MTX there were 8 complete and 1 partial remissions. The complete plus partial remission rate is 64% for VCR and 53% for MTX. The duration of response was superior in the MTX‐treated group, with a median remission duration of 315 days; the 4 patients above the median are still in remission. With VCR therapy, the median was 96 days, and all patients have relapsed. Maintenance therapy also improved the duration of remission, with a median of 20 months, compared to 79 days with no maintenance. Thus, in this clinical trial the best results were obtained when methotrexate plus prednisone were used for induction, followed by methotrexate maintenance therapy.
AB - Twenty‐eight children, ages 2 months to 13 years, with a diagnosis of reticuloendotheliosis were treated on a random basis with either vincristine (VCR) 2 mg/m2/week or methotrexate (MTX) 30 mg/m2 twice a week. Both groups received prednisone 40 mg/m2/day. The responders received randomly either MTX 30 mg/m2 twice weekly or no maintenance therapy. Of the 11 patients receiving VCR, 2 achieved complete and 5 partial remissions. Among 17 treated with MTX there were 8 complete and 1 partial remissions. The complete plus partial remission rate is 64% for VCR and 53% for MTX. The duration of response was superior in the MTX‐treated group, with a median remission duration of 315 days; the 4 patients above the median are still in remission. With VCR therapy, the median was 96 days, and all patients have relapsed. Maintenance therapy also improved the duration of remission, with a median of 20 months, compared to 79 days with no maintenance. Thus, in this clinical trial the best results were obtained when methotrexate plus prednisone were used for induction, followed by methotrexate maintenance therapy.
UR - http://www.scopus.com/inward/record.url?scp=0016268480&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197410)34:4<1011::AID-CNCR2820340408>3.0.CO;2-S
DO - 10.1002/1097-0142(197410)34:4<1011::AID-CNCR2820340408>3.0.CO;2-S
M3 - Article
C2 - 4608879
AN - SCOPUS:0016268480
SN - 0008-543X
VL - 34
SP - 1011
EP - 1017
JO - Cancer
JF - Cancer
IS - 4
ER -